Impact of Molecular Testing on Diagnostic Accuracy and Amendment Rates in Liver Tumor Cases
Dr. Eric Nguyen Co-Presented at USCAP 2025 Annual Meeting
CellNetix pathologist, Dr. Eric Nguyen, co-presented a poster titled “Impact of Molecular Testing on Diagnostic Accuracy and Amendment Rates in Liver Tumor Cases” at the USCAP 114th Annual Meeting in Boston, along with Dr. Xiaoqin Liu, UCSF Medical Center; Dr. Dorukhan Bahceci, Memorial Sloan Kettering Cancer Center; and Dr. Sanjay Kakar, University of California, San Francisco. The research study examines the impact of molecular testing on amendment rates and improving diagnostic accuracy in liver tumor cases.
The diagnosis of a subset of liver tumors cannot be established based on morphology and immunohistochemistry; molecular testing can be helpful for diagnosis in these cases. The study found that molecular testing yielded useful information for diagnosis, site of origin and/or molecular profiling in a majority of cases and that molecular testing should be incorporated in routine diagnostic workflow in these situations. Results of molecular testing are often reported as an amendment when a change in diagnosis is involved, which may be viewed by some metrics as an indicator of interpretive error. However, in this setting, since the amended reports provide a more accurate diagnosis, it should instead be regarded as a positive indicator of quality.
